Aminooxyacetic acid hemihydrochloride is a malate-aspartate shuttle (MAS) inhibitor which also inhibits the GABA degradating enzyme GABA-T. AOA hemihydrochloride dose-dependently decreases the survival of C6 glioma cells. Aminooxyacetic acid hemihydrochloride treatment produces a significant increase in the percentage of the cells arrested in the stage of G0/G1, as well as a significant decrease in the percentage of the cells at S phase and G2/M phase.
The accumulation of GABA in cerebellum and whole brain is initially very rapid, being significantly increased already 5 min after the injection of Aminooxyacetic acid hemihydrochloride (AOAA). The rapid initial accumulation becomes gradually slower and maximal levels (400 to 600 % of the control levels) are reached 2 to 6 h after Aminooxyacetic acid hemihydrochloride. Still 24 h after Aminooxyacetic acid hemihydrochloride the GABA levels are elevated by about 250%.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Formula||NH2OCH2COOH · 0.5HCl|
|Solubility||DMSO: 40 mg/mL|
|Storage||4°C, protect from light, dry, sealed|
Malate-aspartate shuttle inhibitor aminooxyacetic acid leads to decreased intracellular ATP levels and altered cell cycle of C6 glioma cells by inhibiting glycolysis.
Wang C, et al. Cancer Lett. 2016 Aug 1;378(1):1-7. PMID: 27157912.
Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate.
Korangath P, et al. Clin Cancer Res. 2015 Jul 15;21(14):3263-73. PMID: 25813021.
|Related GABA Receptor Products|
SSD114 hydrochloride is a GABAB receptor positive allosteric modulator.
Pipequaline (PK-8165) is a partial benzodiazepine receptor agonist with anxiolytic activity.
AZD-7325 is a GABA-Aα2,3 -selective receptor modulator.
ONO-8590580 is a GABAAα5 negative allosteric modulator which enhances long-term potentiation and improves cognitive deficits in preclinical models.
LAU159 is a potent, functionally selective α6β3γ2 GABAA receptor modulator.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.